It is well known that ALB and liver function abnormalities are rarely seen in the early stage of NAFLD, so it may be difficult to detect potential NAFLD risks through conventional biochemical markers [22]. This evidence concerns the gene ALB and metabolic dysfunction-associated steatotic liver disease.